NDAINJECTIONINJECTABLE
Approved
Dec 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
NIMBEX (cisatracurium besylate) by AbbVie is end-plate to antagonize the action of acetylcholine, resulting in blockade of neuromuscular transmission. First approved in 1995.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NIMBEX (cisatracurium besylate) is a neuromuscular blocking agent administered by injection that antagonizes acetylcholine at the neuromuscular end-plate to produce paralysis during anesthesia and mechanical ventilation. It works by blocking neuromuscular transmission and can be reversed with acetylcholinesterase inhibitors such as neostigmine. The drug is used in perioperative settings to facilitate intubation and maintain muscle relaxation during surgery.
LOE Approaching
As LOE approaches, the commercial team is likely contracting; opportunities may shift toward managed care, pricing strategy, or transition planning rather than growth-focused sales expansion.
Mechanism of Action
end-plate to antagonize the action of acetylcholine, resulting in blockade of neuromuscular transmission. This action is antagonized by acetylcholinesterase inhibitors such as neostigmine.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NIMBEX offers stability in a mature, established market with predictable patient populations and clinical use, but limited growth opportunities as the product approaches loss of exclusivity. Career advancement may be constrained; this role is best suited for professionals seeking to consolidate expertise in specialty pharmaceuticals or transition into adjacent areas like managed care or biosimilar strategy.
Brand Manager
Worked on NIMBEX at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.